GlassScriptPhysician profile
Gopal G Krishna
NPI 1073692083
$83,526.77
in general payments reported to CMS, 2019-2025
32 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $7,374 · 2021: $15K · 2022: $24K · 2023: $1,410 · 2024: $6,004 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,730 · Consulting Fee: $2,550 · Travel and Lodging: $2,219 · Education: $44.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,730.29 |
| Consulting Fee | $2,550.00 |
| Travel and Lodging | $2,219.09 |
| Education | $44.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30,054.25 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $28,171.07 | 2019-2023 | Veltassa |
| Akebia Therapeutics INC | $7,367.85 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $6,909.44 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $4,208.21 | 2021-2025 | |
| Csl Behring | $2,397.84 | 2024 | |
| Amgen INC. | $928.40 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Travere Therapeutics, INC. | $512.24 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $466.70 | 2019-2023 | Rayaldee |
| Calliditas Therapeutics US INC. | $443.00 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $316.47 | 2019-2025 | Jynarque, Voyxact |
| Glaxosmithkline, LLC. | $313.32 | 2021-2025 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $264.66 | 2023-2025 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $199.87 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $167.28 | 2021-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $166.54 | 2021-2023 | Cardiomems |
| Aurinia Pharma U.S., INC. | $115.22 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $113.01 | 2020-2023 | Krystexxa |
| Novo Nordisk INC | $70.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Alexion Pharmaceuticals, INC. | $41.92 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.38 | 2022-2025 | Jardiance |
| Kyowa Kirin, INC. | $40.32 | 2022-2025 | |
| Amag Pharmaceuticals, INC. | $38.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $37.74 | 2019 | |
| Apellis Pharmaceuticals, INC. | $35.58 | 2025 | Empaveli |
| Covidien LP | $25.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.89 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $17.07 | 2019 | |
| Daiichi Sankyo INC. | $14.98 | 2019 | |
| Hikma Pharmaceuticals USA | $14.02 | 2019 | |
| Avion Pharmaceuticals | $14.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Krishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.